Exhibiting at VIV Asia 2025

Shanghai Moxi Biological Technology Co., Ltd. is a high-tech enterprise dedicated to the development, production, and global distribution of veterinary active pharmaceutical ingredients (APIs). Based in Shanghai, China, the company specializes in the manufacture of fermentation-based antibiotics and coccidiostats for use in animal health products worldwide. With a focus on safety, efficacy, and innovation, Moxi has positioned itself as a strategic partner for pharmaceutical and animal health companies across international markets.

Company Background

Shanghai Moxi Biological Technology was established to fill a critical niche in the global supply of high-purity veterinary APIs. The company integrates biotechnological fermentation, downstream purification, and pharmaceutical-grade processing to produce key molecules used in animal feed and treatment. Its Shanghai-based headquarters is supported by modern GMP-aligned production facilities, R&D labs, and global quality assurance systems.

Moxi has earned recognition as a National High-Tech Enterprise, a designation that reflects its continuous investment in R&D and regulatory compliance. The company’s founding team includes microbiologists, fermentation engineers, and pharmaceutical technologists with decades of experience in veterinary drug production.

Core Business and Product Portfolio

Shanghai Moxi specializes in the manufacture of fermentation-derived veterinary active ingredients. Its key offerings include:

• Nosiheptide

  • A potent polypeptide antibiotic used primarily as a feed additive for poultry
  • Exhibits strong activity against Gram-positive bacteria, including Clostridium and Streptococcus
  • Benefits include improved weight gain and feed conversion rates in broilers and layers
  • Widely regarded for its low cross-resistance and minimal residue risk

• Avilamycin

  • Another fermentation-derived antibiotic with action against Gram-positive bacteria
  • Used in pigs and poultry to promote growth and control infections
  • Regarded as safe with a low incidence of resistance, making it suitable for AGP (antibiotic growth promoter) replacement strategies

• Coccidiostat Series Products

  • Though specific products are not listed, Moxi offers anticoccidial APIs tailored to poultry feed applications
  • Designed to support prevention of coccidiosis in intensive farming environments

• Antibiotic Series Products

  • Fermentation-based antibiotic APIs for animal health applications, including custom synthesis and formulation support

These products serve as core components in medicated feed premixes and veterinary formulations produced by global feed and pharma companies.

Unique Selling Proposition (USP)

Moxi's strategic advantages include:

• Fermentation-based manufacturing expertise that ensures purity, yield efficiency, and regulatory consistency
• Focus on low-residue, non-cross-resistant antibiotics well-suited for global export compliance
• In-house analytical capabilities supporting USP/EP/CP specification alignment
• Ability to provide technical dossiers, stability data, and documentation support for product registration in regulated markets
• Flexible production scale, suitable for both bulk orders and customized batches

Its niche focus on veterinary APIs rather than finished formulations enables Moxi to specialize deeply and collaborate closely with formulation partners worldwide.

Financial & Export Performance

Though Shanghai Moxi does not publish financial statements, available market data and B2B listings suggest significant and sustained export activity:

• Export Markets: Southeast Asia, South Asia, Latin America, Eastern Europe
• Verified presence on B2B trade platforms like Alibaba and Made-in-China with multiple product listings
• Products frequently featured in tender submissions and contract manufacturing partnerships with feed and veterinary drug companies
• Multiple contacts listed for international business, indicating a structured export management process

Moxi’s APIs are known for high batch-to-batch consistency and robust quality documentation, driving repeat purchases in competitive procurement settings.

Target Market

Moxi serves:

• Veterinary pharmaceutical companies
• Feed additive and premix manufacturers
• Animal health product importers and distributors
• Formulation R&D labs and contract manufacturers
• Government-approved bulk drug procurement programs

Its APIs are used across poultry, swine, and ruminant feed markets, especially in regions aiming to reduce broad-spectrum antibiotic use while maintaining production efficiency.

Capabilities

Shanghai Moxi operates under a comprehensive manufacturing and quality assurance framework:

• Fermentation tanks and bioreactors for microbial culture of antibiotic-producing strains
• Downstream processing systems for filtration, extraction, and crystallization
• Analytical labs with HPLC, GC, UV-spectrophotometry, and microbiological testing equipment
• Packaging and labeling infrastructure tailored to API-level product standards
• Capacity for technical dossier preparation and registration support in over 20 markets

The company adheres to strict environmental and waste management policies, aligning with China's green production mandates.

Certifications and Compliance

Moxi maintains robust compliance with national and international pharmaceutical standards:

• GMP-aligned production systems under the supervision of China's Ministry of Agriculture and Rural Affairs (MARA)
• Products conform to Chinese Veterinary Pharmacopoeia (CVP) and specifications equivalent to USP/EP standards
• Internal documentation and auditing procedures modeled on ISO9001 practices
• Ability to provide DMFs and CTDs (Common Technical Documents) for product registration

These standards make Moxi’s APIs suitable for export to both regulated and semi-regulated markets.

Customer Testimonials

Although public testimonials are not available, customer interactions via trade platforms and repeat purchasing behavior indicate:

• High levels of satisfaction with product quality and consistency
• Strong confidence in technical support and documentation accuracy
• Favorable comparisons of Moxi’s Nosiheptide and Avilamycin with global benchmark producers
• Appreciation for fast response times and flexible shipping arrangements

Moxi is often chosen for medium- to high-volume supply agreements due to its reliability and cost-performance ratio.

Achievements and Recognition

• Recognized as a National High-Tech Enterprise in China
• Developed proprietary strain optimization and fermentation processes to improve yield and purity
• Participated in national veterinary drug innovation initiatives
• Earned multiple certifications and compliance badges on B2B and regulatory platforms
• Supported international customers in over 25 countries with API registration and regulatory approvals

Shanghai Moxi Biological Technology Co., Ltd. is at the forefront of veterinary API manufacturing in China. With its biotech-driven approach, strict quality standards, and export orientation, the company continues to play a vital role in global animal health and feed efficiency improvement.